News stories about Tenax Therapeutics (NASDAQ:TENX) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tenax Therapeutics earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.4421110376448 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of NASDAQ:TENX traded down $0.01 during trading on Thursday, reaching $6.13. The stock had a trading volume of 561 shares, compared to its average volume of 208,257. Tenax Therapeutics has a 1-year low of $4.40 and a 1-year high of $15.80.
Separately, ValuEngine upgraded Tenax Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 27th.
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.